The Food and Drug Administration has approved a new MRI contrast agent developed by Nycomed Amersham for liver studies. The Buckinghamshire, U.K., company announced on Dec. 1 that Teslascan received the FDA's go-ahead. In addition to Nycomed Amersham's
The Food and Drug Administration has approved a new MRI contrast agent developed by Nycomed Amersham for liver studies. The Buckinghamshire, U.K., company announced on Dec. 1 that Teslascan received the FDA's go-ahead. In addition to Nycomed Amersham's marketing effort, Teslascan will be sold in the U.S. by Schering subsidiary Berlex Laboratories of Wayne, NJ. Berlex gained rights to Teslascan in 1992 in exchange for settling its claim that Nycomed's Omniscan MRI agent infringed on patents Schering holds for its Magnevist product (SCAN 8/26/92).
Berlex will market Teslascan under its own label and trade name, but the company has not yet determined what it will call the product, according to a Berlex spokesperson. Teslascan is not covered by Berlex's contrast media licensing agreement with Abbott Laboratories, which distributes Magnevist and x-ray contrast agent Ultravist
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.